Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA accepts NDA filing for bremelanotide for hypoactive sexual desire disorder

June 5, 2018

Myalepta receives positive CHMP opinion for generalized and partial lipodystrophy

June 5, 2018

Hepagene Therapeutics describes farnesoid X receptor agonists

June 5, 2018

U.S. orphan designation granted to Alnylam Pharmaceuticals siRNA therapy for amyloidosis

June 4, 2018

Tegsedi receives positive opinion in Europe

June 4, 2018

Mithra announces further positive phase IIb efficacy and safety results for Donesta

June 1, 2018

FDA approves Imvexxy to treat moderate to severe dyspareunia due to menopause

May 30, 2018

Galafold launched in Japan for Fabry disease

May 30, 2018

Kowa to launch Parmodia in Japan for hyperlipidemia

May 29, 2018

JCR obtains approval in Brazil to begin phase II trial of JR-141 for Hunter's syndrome

May 29, 2018

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 14, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...